Dear Doctor: Your patient is off his/her medication

Sending provider letters is associated with a significant impact on medication adherence

This study looked at members taking drugs in the three CMS Star rating categories: diabetes, high cholesterol and high blood pressure. When some of those members became non-adherent, their doctors were sent letters. A significant percentage of the members (up to 16%) whose doctors received letters became adherent again. This simple intervention provided an effective result.

Impact of provider mailings on medication adherence in Medicare Part D members (Spring 2014)

About Prime Therapeutics

Prime Therapeutics LLC (Prime) is a diversified pharmacy solutions organization serving health plans, employers and government programs. Prime is collectively owned by 19 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those plans. Magellan Rx Management LLC, a Prime Therapeutics LLC Company, is a pioneer in specialty and medical drug management and a leader in serving public sector state government programs. Together Prime and Magellan Rx provide a wide range of clients with solutions that bridge the distance between medical and pharmacy management. For more information visit primetherapeutics.com and magellanrx.com or follow us on X (Twitter) at @Prime_PBM and @Magellan_Rx.

Related news

Perspectives

July 25, 2024

Quarterly Drug Pipeline: July 2024

Clinical insights and competitive intelligence on anticipated drugs in development

Stories

July 22, 2024

Introducing the latest issue of our medical and pharmacy benefit management report

The summer 2024 issue of the Magellan Rx Report provides insights on the industry’s most groundbreaking managed care solutions in some of the most complex areas of health care

Perspectives

July 22, 2024

Oncology Insights: 2024 ASCO Annual Meeting key findings

Findings from this year’s American Society of Clinical Oncology (ASCO) Annual Meeting will likely lead to clinical practice changes and U.S. Food and Drug Administration (FDA) drug approvals or expansions

View all news